IgA肾病治疗的疗效与安全性比较:随机对照试验的网络荟萃分析
该网络荟萃分析纳入21项随机对照试验共1822例蛋白尿>1 g/d的IgA肾病患者,比较7种干预措施的疗效与安全性。结果显示RASi联合类固醇在预防ESRD或血肌酐翻倍方面最优,RASi联合尿激酶在诱导临床缓解方面排名最高,各干预措施严重不良事件无统计学差异。
要点
- RASi联合类固醇可能是兼顾减少蛋白尿与长期肾脏保护的最佳治疗选择。
- RASi联合尿激酶在诱导临床缓解方面SUCRA排名最高(0.912)。
- 各干预措施间严重不良事件发生率无统计学差异。
核心结论
- RASi联合类固醇可能是既减少蛋白尿又维持长期肾脏保护的最佳治疗选择。
研究设计与样本
- 研究为网络荟萃分析,检索PubMed、Embase和Cochrane Library,纳入21项随机对照试验共1822例蛋白尿>1 g/d的IgA肾病患者,比较7种干预措施。
主要发现
- 诱导临床缓解排名前三为RASi联合尿激酶(SUCRA 0.912)、类固醇联合扁桃体切除(SUCRA 0.710)、RASi联合类固醇(SUCRA 0.583)。
- 预防ESRD或血肌酐翻倍方面RASi联合类固醇最优(SUCRA 0.012),其次为RASi(SUCRA 0.282)和类固醇(SUCRA 0.494),霉酚酸酯最差(SUCRA 0.644)。
- 所有干预措施间严重不良事件发生率无统计学差异。
关键数值与推荐
- 纳入标准为蛋白尿>1 g/d的IgA肾病患者,比较临床缓解率和/或ESRD和/或严重不良事件。
- 采用SUCRA对干预措施进行排序。
临床怎么用
- 对于蛋白尿>1 g/d的IgA肾病患者,RASi联合类固醇可作为兼顾减少蛋白尿与长期肾脏保护的优先选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study aims to compare the relative efficacy and safety of different interventions for IgA nephropathy (IgAN) with proteinuria more than 1 g/d by using network meta-analysis. We searched PubMed, Embase, and the Cochrane Library for studies compared the rate of clinical remission and/or end-stage renal disease (ESRD) and/or serious adverse events in IgAN patients with proteinuria (>1 g/d). The surface under the cumulative ranking area (SUCRA) was calculated to rank the interventions. A total of 21 randomized controlled trials with 1822 participants were included for the comparisons of 7 interventions. The rank of the most effective treatments to induce clinical remission was renin-angiotensin system inhibitors (RASi) plus urokinase, steroid plus tonsillectomy, and RASi plus steroid with a SUCRA of 0.912, 0.710, and 0.583, respectively. As for the prevention of ESRD or doubling of serum creatinine, RASi plus steroid (SUCRA 0.012) was the most effective, followed by RASi (SUCRA 0.282) and steroid (SUCRA 0.494), leaving mycophenolate mofetil as the least effective (SUCRA 0.644). There was no statistical difference among all interventions in the occurrence of serious adverse events. The current network meta-analysis demonstrated for the first time that RASi plus steroid is probably the best therapeutic choice, not only for reducing proteinuria but also for maintaining long-term renal protection.
引用
- Yang P, Zou H, Xiao B, et al. Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials. Kidney Int Rep. 2018. PMID: 29989013. doi:10.1016/j.ekir.2018.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。